Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dorte Ancher Larsen

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Personalized Medicine|February 23, 2024
Two-Year Results of 0.01% Atropine Eye Drops and 0.1% Loading Dose for Myopia Progression Reduction in Danish Children: A Placebo-Controlled, Randomized Clinical TrialNiklas Cyril Hansen, Anders Hvid-Hansen, Flemming Møller, et al.
BMC Ophthalmology|October 31, 2023
Safety and efficacy of 0.01% and 0.1% low-dose atropine eye drop regimens for reduction of myopia progression in Danish children: a randomized clinical trial examining one-year effect and safetyNiklas Cyril Hansen, Anders Hvid-Hansen, Flemming Møller, et al.
Journal of Personalized Medicine|December 24, 2025
Correction: Hansen et al. Two-Year Results of 0.01% Atropine Eye Drops and 0.1% Loading Dose for Myopia Progression Reduction in Danish Children: A Placebo-Controlled, Randomized Clinical Trial. <i>J. Pers. Med.</i> 2024, <i>14</i>, 175Niklas Cyril Hansen, Anders Hvid-Hansen, Flemming Møller, et al.
Acta Ophthalmologica|July 18, 2022
Prevalence of allergic sensitization with vernal keratoconjunctivitis: A systematic review with meta-analysesMarie Louise Roed Rasmussen, Maria D'Souza, Divan Gabriel Topal, et al.
Ugeskrift for Laeger|December 4, 2019
[Diagnosis, monitoring and treatment of tuberous sclerosis complex]Mark Reinhard, Lone Sunde, Mia Gebauer Madsen, et al.
Human Genetics|October 15, 2021
TUBB3 Arg262His causes a recognizable syndrome including CFEOM3, facial palsy, joint contractures, and early-onset peripheral neuropathyMary C Whitman, Brenda J Barry, Caroline D Robson, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Personalized Medicine|February 23, 2024
Two-Year Results of 0.01% Atropine Eye Drops and 0.1% Loading Dose for Myopia Progression Reduction in Danish Children: A Placebo-Controlled, Randomized Clinical TrialNiklas Cyril Hansen, Anders Hvid-Hansen, Flemming Møller, et al.
BMC Ophthalmology|October 31, 2023
Safety and efficacy of 0.01% and 0.1% low-dose atropine eye drop regimens for reduction of myopia progression in Danish children: a randomized clinical trial examining one-year effect and safetyNiklas Cyril Hansen, Anders Hvid-Hansen, Flemming Møller, et al.
Journal of Personalized Medicine|December 24, 2025
Correction: Hansen et al. Two-Year Results of 0.01% Atropine Eye Drops and 0.1% Loading Dose for Myopia Progression Reduction in Danish Children: A Placebo-Controlled, Randomized Clinical Trial. <i>J. Pers. Med.</i> 2024, <i>14</i>, 175Niklas Cyril Hansen, Anders Hvid-Hansen, Flemming Møller, et al.
Acta Ophthalmologica|July 18, 2022
Prevalence of allergic sensitization with vernal keratoconjunctivitis: A systematic review with meta-analysesMarie Louise Roed Rasmussen, Maria D'Souza, Divan Gabriel Topal, et al.
Ugeskrift for Laeger|December 4, 2019
[Diagnosis, monitoring and treatment of tuberous sclerosis complex]Mark Reinhard, Lone Sunde, Mia Gebauer Madsen, et al.
Human Genetics|October 15, 2021
TUBB3 Arg262His causes a recognizable syndrome including CFEOM3, facial palsy, joint contractures, and early-onset peripheral neuropathyMary C Whitman, Brenda J Barry, Caroline D Robson, et al.
Pageof 2